Mahamaya Lifesciences Ltd544611Corporate

Latest results: Mar 2026 3 quarters of data

—

MCap —

Live price not available

Mahamaya Lifesciences Ltd — Stock analysis & AI research Mahamaya Lifesciences Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹166 Cr

Sales · Mar 2026

₹17 Cr

Operating Profit · Mar 2026

10.2%

OPM % · Mar 2026

₹8 Cr

Net Profit · Mar 2026

₹3.48

EPS · Mar 2026

📝 Mahamaya Lifesciences Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Mahamaya Lifesciences Ltd reported revenue of ₹166 crore for the quarter ended March 2026 (Q4 FY26).

Net profit stood at ₹8 crore. Earnings per share (EPS) came in at ₹3.48.

Operating profit stood at ₹17 crore — an operating margin (OPM) of 10.2%.

Shareholding pattern

As of Mar 2026, promoters held 56.35%, foreign institutional investors (FIIs) 4.77%, domestic institutional investors (DIIs) 2.52%, public shareholders 36.35% of Mahamaya Lifesciences Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

N/A

Current Price ?

N/A

P/E ?

N/A

Industry P/E ?

N/A

P/B ?

N/A

P/S ?

N/A

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

20.0%

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹166 Cr

PAT — latest qtr ?

₹8 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

34%

Sales growth (5y) ?

N/A

Profit growth (3y) ?

64%

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹91 Cr

Debt to Equity ?

0.75

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

56.35%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

N/A

Return 6 months ?

N/A

🗓️ Quarterly results (3 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2024	Sep 2025	Mar 2026	YoY %	QoQ %
Sales	146	163	166	—	—
Operating Profit	13	15	17	—	—
Other Income	1	1	1	—	—
Interest	4	4	4	—	—
Depreciation	1	1	1	—	—
Profit Before Tax	10	11	12	—	—
Net Profit	7	8	8	—	—
EPS	4.08	4.71	3.48	—	—
OPM %	8.9%	9.2%	10.2%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	1	1	18	23	+27.8%
Reserves	18	23	32	99	+209.4%
Borrowings	24	55	58	91	+56.9%
Other Liabilities	34	33	81	98	+21.0%
Total Liabilities	78	112	188	310	+64.9%
Fixed Assets	21	21	27	38	+40.7%
CWIP	2	3	4	6	+50.0%
Investments	0	0	0	0	—
Other Assets	54	88	157	267	+70.1%
Total Assets	78	112	188	310	+64.9%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	1	-23	1	-30	-3100.0%
Cash from Investing Activity	-3	-2	-8	-16	-100.0%
Cash from Financing Activity	2	24	9	81	+800.0%
Net Cash Flow	1	-0	1	35	+3400.0%
Free Cash Flow	-2	-25	-8	-46	-475.0%
CFO/OP	24%	-162%	12%	-75%	-725.0%

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	25	64	67	78	+16.4%
Inventory Days	109	137	167	—	—
Days Payable	87	61	92	—	—
Cash Conversion Cycle	48	140	142	78	-45.1%
Working Capital Days	9	14	29	49	+69.0%
ROCE %	20%	21%	26%	20%	-23.1%

👥 Shareholding (latest 2 periods)

Metric	Nov 2025	Mar 2026	% Chg
Promoters	56.35%	56.35%	+0.0%
FIIs	6.39%	4.77%	-25.4%
DIIs	4.67%	2.52%	-46.0%
Public	32.60%	36.35%	+11.5%
No. of Shareholders	1,034	584	-43.5%

⚖️ Peer comparison

Peer comparison unavailablePeer comparison unavailable — industry and sector are not classified for this symbol.

❓ Frequently asked questions

What was Mahamaya Lifesciences Ltd's revenue in Q4 FY26?